BioXcel Therapeutics (BTAI) Shares Outstanding (Weighted Average) (2017 - 2026)

BioXcel Therapeutics' Shares Outstanding (Weighted Average) history runs 10 years deep, the most recent figure standing at $23.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 387.61% year-over-year to $23.6 million; the TTM figure through Mar 2026 stood at $23.6 million (up 387.61% YoY), while the FY2025 annual figure was $12.2 million, up 381.58% from the prior year.
• Shares Outstanding (Weighted Average) was $23.6 million for Q1 2026 at BioXcel Therapeutics, up from $12.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $29.3 million in Q3 2023 to a low of $1.8 million in Q4 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $16.0 million across 5 years, with a median of $14.2 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) tumbled 93.5% in 2023, then soared 500.0% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $28.0 million in 2022, then sank by 93.5% to $1.8 million in 2023, then soared by 39.21% to $2.5 million in 2024, then soared by 381.58% to $12.2 million in 2025, then jumped by 93.08% to $23.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $23.6 million (Q1 2026), $12.2 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.